1. Introduction {#sec1}
===============

The relationship between blood glucose metabolism and cancer has been under extensive study for many years, particularly for those diagnosed with type 2 diabetes mellitus (T2DM) \[[@B1]\]. In some epidemiological studies, the high morbidity of malignancies in individuals with long-term aberrant fasting blood glucose (FBG) or T2DM has been established \[[@B2], [@B3]\], and examples have been provided in breast cancer \[[@B3]\], esophageal cancer \[[@B4]\], liver cancer \[[@B5]\], and colorectal cancer (CRC) \[[@B3], [@B6]\], which is one of the leading causes of cancer-related death in China \[[@B7]\].

Notably, in addition to high FBG promoting cancer aggression \[[@B8]\], it is also associated with a poor prognosis for patients \[[@B9], [@B10]\]. For example, Contiero et al. reported a study that included 1,261 stage I-III breast cancer patients and found that high FBG correlated with not only distant metastasis or recurrence but also death \[[@B9]\]. Luo et al. also performed a study with 342 non-small-cell lung cancer (NSCLC) patients and found that high FBG was linked to a 69% excess risk of all-cause mortality \[[@B10]\]. However, in contrast, Cui et al. conducted a study of 391 patients with CRC, including 116 patients with high FBG, and found that FBG was linked to larger tumor diameters, lower tumor differentiation, advanced TNM stage, and a more ulcerative type but had no influence on distant metastasis or overall survival (OS) \[[@B11]\]. Interestingly, cancer treatment approaches can also affect FBG, and typical examples have been seen in breast or prostate cancer sufferers who receive endocrine therapies \[[@B12], [@B13]\]. In addition, it has been reported that surgery also improves glucose metabolism in pancreatic cancer patients with prior T2DM \[[@B14]\]. Nonetheless, studies concerning the role of FBG in CRC patients treated with curable resection, particularly in those with a prior normal FBG, have not been reported.

Although it is mainly regulated by insulin, the level of FBG in individuals has been found to be closely related to some characteristics, including body mass index (BMI) \[[@B15], [@B16]\] and the neutrophil-lymphocyte ratio (NLR). The NLR was found to be positively associated with FBG in patients with T2DM or high FBG \[[@B17]\] but was negatively correlated with FBG in normal subjects \[[@B18]\]. In this study, we aimed to explore the prognostic role of postoperative FBG and other clinicopathological features, including the abovementioned BMI and NLR, in stage I-III CRC patients with a prior normal FBG.

2. Materials and Methods {#sec2}
========================

2.1. Patient Enrollment {#sec2.1}
-----------------------

From January 2011 to October 2014, 120 patients with colorectal adenocarcinoma (according to the 7^th^ edition of the American Joint Committee on Cancer Staging) staged I-III were collected at Hainan Hospital of PLA General Hospital. Patients with the following criteria were excluded: (1) age \< 18 years old; (2) a history of previous T2DM or elevated FBG beyond the upper limit (ref: 3.4-6.1 mmol/L); (3) multiple or recurrent malignancies or *in situ* lesions; (4) a history of previous neoadjuvant therapy; (5) complications such as infection, obstruction, and bleeding after surgery; (6) unsuccessful oral feeding within 14 days after the operation; and (7) no record of postoperative FBG or a follow-up date. Clinicopathological parameters included age (\<60 or ≥60 years old), sex, BMI, CEA (ref: 0-5 *μ*g/L), and CA19-9 (ref: 0.1-37 *μ*g/mL) values, and the results of routine blood tests including hemoglobin (HGB; males: 137-179 g/L and females: 116-155 g/L), absolute white blood cell (WBC) counts (ref: 3.5-10^9^/L), monocyte (MON) counts (ref: 0.10-0.8^9^/L), platelets (PLT; 100-300^9^/L), and serum albumin (ALB; ref: 35-50 g/L) were recorded before the operation. In addition, pathological results regarding tumor location, histological grade, invasive depth, maximum tumor diameter, etc., were recorded. Postoperative adjuvant therapies were recorded. The study was supervised by the ethics committee of Hainan Hospital of PLA General Hospital (approved ID: 301HLFYLL15), and written informed consent was not needed since this was a retrospective study.

2.2. Determination of Preoperative/Postoperative FBG and NLR {#sec2.2}
------------------------------------------------------------

Routine laboratory tests were performed between 6:00 and 9:00 am on peripheral venous blood within 1 month before surgery (preoperative) and at least 14 days to 1 month after surgery (postoperative). In addition, FBG values in patients with available records 3-6 months after the operation were also collected. The BMI and NLR were determined as previously described \[[@B19], [@B20]\].

2.3. Follow-Up Procedure and Definition of Disease-Free Survival (DFS) {#sec2.3}
----------------------------------------------------------------------

Patient follow-up was achieved by telephone or a visit to the medical records department at the hospital at intervals of 3-6 months for the first 3 years and 6-12 months for the next year. DFS was defined as the point from the date of operation until the date of first recurrence or death from any cause. The primary study endpoint was 3 years DFS, as defined in a previous study \[[@B21]\], and the last follow-up point occurred in October 2019.

2.4. Statistical Analysis {#sec2.4}
-------------------------

All the statistical analyses were conducted by using SPSS 20.0 software (SPSS Inc., Chicago, IL, USA). Receiver operating characteristic (ROC) curve analysis was used to determine the optimal cut-off value for FBG, and its relationship with other clinicopathological parameters was calculated by the *χ*^2^ test, Fisher\'s exact test, Student\'s *t*-test, or the Mann--Whitney *U* test when appropriate. Kaplan-Meier (K-M) survival curves were constructed to compare patients with low and high FBG, and significant differences were determined by the log-rank test \[[@B9]\]. Univariate and multivariate analyses were conducted by using the Cox proportional hazards model \[[@B22]\]; the proportional hazards assumption was checked by Schoenfeld residuals for continuous variables \[[@B9]\] or by K-M for categorical variables. A double-sided *P* \< 0.05 was considered statistically significant.

3. Results {#sec3}
==========

3.1. Demographic Characteristics and Differences in Postoperative FBG according to Various Clinicopathological Parameters {#sec3.1}
-------------------------------------------------------------------------------------------------------------------------

In total, 40 female and 80 male patients were included, and the mean age of the patients was 57.87 years old (range: 24-85 years old), with a medium follow-up time of 45.08 months (range: 1-81 months). There were 21, 53, and 46 patients with stage I, II, and III disease, respectively. As shown in [Figure 1](#fig1){ref-type="fig"}, with a cut-off point of 5.11 mmol/L, postoperative FBG had a sensitivity and specificity of 38.50% and 32.10%, respectively, in predicting DFS (AUC = 0.64, *P* = 0.01). When patients were divided into low or high groups according to this cut-off point, a relatively high postoperative FBG could be found in older age (*P* = 0.01), left-located tumor (*P* = 0.02), smaller tumor diameter (*P* = 0.01), node negative involvement (*P* = 0.01), lesser positive lymph nodes (*P* = 0.02), and high preoperative HGB (*P* = 0.01) ([Table 1](#tab1){ref-type="table"}). In addition, 80 patients were available for the postoperative 3-6 months FBG, and 47 maintained a high FBG compared to their preoperative values. In these selected cases, the postoperative FBG failed to display a significant role in predicting DFS (AUC = 0.40, *P* = 0.15). (Data not included in [Table 1](#tab1){ref-type="table"}).

3.2. Predictive Value of Postoperative FBG for DFS {#sec3.2}
--------------------------------------------------

According to K-M analyses, we then examined the predictive value of postoperative FBG for DFS. As shown in [Figure 2](#fig2){ref-type="fig"}, patients with a high postoperative FBG displayed a significantly better DFS than those with a low postoperative FBG (48.80 ± 22.12 months *vs*. 40.06 ± 24.36 months, *P* = 0.04).

3.3. Univariate and Multivariate Analyses for the Factors Correlated with DFS {#sec3.3}
-----------------------------------------------------------------------------

As shown in [Table 2](#tab2){ref-type="table"}, according to univariate tests, preoperative CEA and CA19-9 levels, invasive depth, maximum tumor diameter, node involvement, number of positive nodes, stage III, BMI, preoperative NLR, ALB, and postoperative FBG correlated with the DFS. According to the HRs obtained, it can be seen that the majority of the above factors played as a risk factors for DFS except ALB and postoperative FBG. A *P* \< 0.05 was used as a cut-off value in multivariate analysis after checking the proportional hazards assumption; the preoperative CEA level, invasive depth, node involvement, and preoperative NLR and ALB were found to be independent prognostic factors; according to the HRs obtained, the invasive depth was the most significant risk factor and only the ALB was a protective factor for the DFS.

4. Discussion {#sec4}
=============

In this study, we found that high postoperative FBG predicted a better DFS for CRC than a low postoperative FBG. In addition, high postoperative FBG correlated with parameters including age, tumor location, maximum tumor diameter, number of positive nodes, and preoperative HGB and NLR as well as a prolonged DFS. Although according to the Cox proportional hazards model, the level of postoperative FBG was less likely to be an independent prognostic factor, these data provide, to the best of our knowledge, the first observation concerning the prognostic role of postoperative FBG in CRC, in particular, within patients with a prior normal FBG.

Postoperative FBG has been reported to play a significant prognostic role in cancer patients. For example, Yang et al. carried out a prospective cohort study with 387 stage I-IV NSCLC patients and found that patients with a low FBG (\<4 mmol/L) had a significantly higher risk of death than those with a high FBG \[[@B23]\]. Wu et al. conducted a study that included 306 stage 0-III esophageal cancer patients who underwent esophagectomy and found that low postoperative FBG was related to poor survival, and an FBG ≤4 mmol/L was independently linked to poor survival \[[@B16]\]. In our study, we selected patients without a background of a prior preoperative aberrant FBG and found that a low postoperative FBG (\<5.11 mmol/L) was associated with poor survival for CRC, which was partially consistent with the results of these studies \[[@B16], [@B23]\]. Notably, we also found that 58.75% (47/80) of patients maintained a relatively high FBG compared to their preoperative value at the 3-6 m follow-up, but FBG failed to present any prognostic value for DFS. Although the study sample size was relatively small, the importance of longitudinal tests of FBG to predict the DFS in patients is important.

Until now, the underlying mechanisms of glucose metabolism in cancer patients were still not fully understood, but glucose metabolism was potentially correlated with some characteristics. In our study, postoperative low FBG was correlated with younger age, disease on the right side of their body, large tumor diameter, more positive nodes, and low preoperative HGB. It is notable that some of these parameters are well-established prognostic factors for CRC. For example, studies have indicated that right-sided tumors have an inferior prognosis in terms of OS in stage III tumors \[[@B24]\] and in those undergoing curative resection of liver metastases \[[@B25]\]. Additionally, a large tumor size was found to be associated with poor OS in those receiving chemotherapy \[[@B26]\]. Additionally, other studies have indicated that younger age \[[@B27]\] and low HGB are associated with poor prognosis in patients \[[@B28]\]. We speculate that these parameters contribute to the link between poor DFS and high postoperative FBG in CRC.

Although studies have indicated that high glucose levels can not only accelerate tumorigenesis \[[@B29]\] but also promote cancer aggression \[[@B8]\], there are still conflicting results. For example, two studies indicated that hyperglycemia inhibited malignant cell spread and metastasis in patients with cancer such as NSCLC \[[@B30], [@B31]\]. In line with these findings, some experimental studies have indicated the consequences of glucose deprivation in CRC. For example, Li et al. indicated that in the human colon cancer cell line HT-29, glucose deprivation increased cell proliferation by 30% when cells were exposed to *γ*-radiation \[[@B32]\]. Hu et al. reported that glucose deprivation resulted in chemoresistance in CRC cells by upregulating transcription factor 4 expression \[[@B33]\]. Additionally, Nishimoto et al. found that glucose deprivation played a central role in the acquisition of antiapoptotic mechanisms by human colorectal cancer cells via activation of hypoxia-inducible factor-1*α* \[[@B34]\]. Recently, a study indicated that cancer dissemination occurred even when the primary lesions were clinically undetectable \[[@B35]\]. However, whether high glucose levels could inhibit remaining cancer cells in patients undergoing curative surgery based on the findings of the above studies is still largely unknown, and more clinical studies are needed in the future.

The present study had many limitations. First, its small sample size may limit the statistical power. Second, taking into consideration the complexity of glucose metabolism in cancer patients, some potential residual confounders, for example, patients received adjuvant therapies would have different glucose metabolism than their counterparts, that may bias the findings. Third, a more prolonged follow-up duration would have allowed the role of postoperative FBG in predicting OS to be determined. Nonetheless, more convincing evidences can only be obtained from prospective randomized controlled studies and fundamental researches in this field in the future.

5. Conclusion {#sec5}
=============

Overall, our results indicate that postoperative FBG plays a temporal prognostic role for stage I-III CRC patients with a prior normal FBG, but FBG was likely not an independent prognostic factor.

The study was conducted with grants from the Sanya Medical and Health Science Innovation Project (2018YW06 and 2016YW08), Chinese Natural Science Foundation (81503391), and Hainan Natural Science Foundation (817352).

Data Availability
=================

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest
=====================

The authors have no conflicts of interest to declare.

![Receiver operating characteristic curve analysis of postoperative FBG in patients.](GRP2020-2482409.001){#fig1}

![Impact of low or high postoperative FBG on disease-free survival.](GRP2020-2482409.002){#fig2}

###### 

Differences in postoperative FBG among different clinicopathological parameters.

                                No. of patients   Postoperative FBG                    
  ----------------------------- ----------------- ------------------- ---------------- ----------
  Age (y)                                                                              **0.01**
   \<60                         62                33                  29               
   ≥60                          58                18                  40               
  Sex                                                                                  0.43
   Female                       40                15                  25               
   Male                         80                36                  44               
  Tumor location                                                                       **0.02**
   Right                        34                20                  14               
   Left                         86                31                  55               
  Histological grade                                                                   0.07
   Well                         4                 0                   4                
   Moderate                     90                36                  54               
   Poor                         26                15                  11               
  CEA level                                                                            0.13
   Normal                       82                31                  51               
   Elevated                     38                20                  18               
  CA19-9 level                                                                         0.08
   Normal                       102               40                  62               
   Elevated                     18                11                  7                
  Invasive depth                                                                       0.36
   T~1+2~                       26                9                   17               
   T~3+4~                       94                42                  52               
  Maximum tumor diameter (cm)                     5.04 ± 2.18         4.14 ± 1.79      **0.01**
  Node involvement                                                                     **0.01**
   N~0~                         72                24                  48               
   N~1+2~                       48                27                  21               
  Positive nodes                120               2.94 ± 5.55         1.46 ± 3.24      **0.02**
  TNM stage                                                                            0.05
   I                            21                5                   16               
   II                           53                21                  32               
   III                          46                25                  21               
  Adjuvant therapies                                                                   **0.04**
   Received                     70                35                  35               
   None                         50                16                  34               
  BMI (kg/m^2^)                 120               22.87 ± 4.18        23.66 ± 3.27     0.33
  Preoperative measures                                                                
   HGB (g/L)                    120               119.27 ± 18.95      127.24 ± 12.55   **0.01**
   WBC (×10^9^/L)               120               6.29 ± 1.84         6.45 ± 1.77      0.64
   NLR                          120               2.66 ± 1.93         2.06 ± 1.20      0.11
   MON (×10^9^/L)               120               0.49 ± 0.20         0.50 ± 0.17      0.87
   PLT (×10^9^/L)               120               245.35 ± 86.91      250.22 ± 98.50   0.96
   ALB (g/L)                    120               39.42 ± 5.04        39.86 ± 2.90     0.85

###### 

Univariate and multivariate analyses of different parameters for prognosis by Cox proportional hazards model.

                                No. of patients   No. of events   Univariate   Multivariate                                    
  ----------------------------- ----------------- --------------- ------------ -------------- ------------ ------------ ------ ------------
  Age (years)                                                                                                                  
   \<60                         62                19              1                                                            
   ≥60                          58                20              0.73         1.12           0.60-2.09                        
  Sex                                                                                                                          
   Female                       80                13              1                                                            
   Male                         40                26              0.96         1.02           0.52-1.98                        
  Tumor location                                                                                                               
   Right                        86                8                                                                            
   Left                         34                31              0.27         1.55           0.71-3.37                        
  Histological grade                                                                                                           
   Well                         26                10              1                                                            
   Moderate+poor                94                29              0.32         0.70           0.34-1.43                        
  CEA level                                                                                                                    
   Normal                       82                17              1                                        1                   
   Elevated                     38                22              **\<0.01**   3.85           2.04-7.28    **\<0.01**   2.85   1.45-5.61
  CA19-9 level                                                                                                                 
   Normal                       102               28              1                                                            
   Elevated                     18                11              **\<0.01**   3.14           1.56-6.33                        
  Invasive depth                                                                                                               
   T~1+2~                       26                2               1                                        1                   
   T~3+4~                       94                37              **0.01**     5.93           1.43-24.61   **0.03**     5.04   1.18-21.45
  Maximum tumor diameter (cm)   120               39              **\<0.01**   1.24           1.07-1.43                        
  Node involvement                                                                                                             
   N~0~                         72                16              1                                                            
   N~1+2~                       48                23              **\<0.01**   2.64           1.39-5.01                        
  Positive nodes                120                               **\<0.01**   1.17           1.11-1.24    **\<0.01**   1.11   1.04-1.18
  TNM stage                                                       **\<0.01**   2.39           1.43-4.01                        
   I                            21                1               1                                                            
   II^a^                        53                16              **0.06**     6.91           0.92-52.12                       
   III^b^                       46                22              **0.01**     12.86          1.73-95.52                       
  Adjuvant therapies                                                                                                           
   Received                     70                27              1                                                            
   None                         50                12              0.10         0.57           0.29-1.12                        
  BMI (kg/m^2^)                 120               39              **0.04**     0.91           0.83-0.99                        
  Preoperative measures                                                                                                        
   WBC (×10^9^/L)               120               39              0.68         1.04           0.87-1.23                        
   HGB (g/L)                    120               39              0.71         1.00           0.98-1.02                        
   NLR                          120               39              **\<0.01**   1.44           1.24-1.67    **\<0.01**   1.35   1.16-1.58
   PLT (×10^9^/L)               120               39              0.61         1.00           1.00-1.00                        
   ALB (g/L)                    120               39              **\<0.01**   0.88           0.81-0.96    **\<0.01**   0.90   0.83-0.97
  Postoperative FBG (mmol/L)    120               39              **0.01**     0.56           0.34-0.88                        

^a,\ b^Compared with stage I.
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